• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Vectrus Shareholders Approve Combination with Vertex; Co. Will Be Renamed V2X, To Trade On NYSE Under Ticker VVX

    6/15/22 4:07:04 PM ET
    $VEC
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VEC alert in real time by email

    Vectrus, Inc. (NYSE:VEC) today announced that based on voting results from the Special Meeting of Shareholders held today, Vectrus shareholders voted to approve the combination with Vertex. Following the close of the transaction, the combined company will be renamed V2X, Inc, and its common stock will trade on the NYSE under a new ticker symbol, "VVX".

    Vectrus Logo.

    "Today's overwhelming approval marks a significant step toward completing our merger with Vertex, and creating one of the leading providers of critical mission solutions and support to defense clients globally," said Chuck Prow, Chief Executive Officer of Vectrus. "Vectrus and Vertex - together as V2X - will be better positioned to meet the mission-essential needs of our clients while delivering cost efficiencies, increased security and resiliency, with more strategic use of resources. We thank all of our stakeholders for their continued support and look forward to completing the pending combination so we can begin unlocking the incredible potential of our combined platform."

    As previously announced, under the terms of the merger agreement, Vertex shareholders will own approximately 62% of the combined company on a fully diluted basis, while Vectrus shareholders will own approximately 38%. The merger is expected to close early in the third quarter of 2022, and remains subject to satisfaction of customary closing conditions, including receipt of regulatory approvals.

    The final voting results will be reported in a Current Report on Form 8-K to be filed with the Securities and Exchange Commission after certification by Vectrus' inspector of elections.

    Get the next $VEC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VEC
    $VRTX

    CompanyDatePrice TargetRatingAnalyst
    Vertex Pharmaceuticals Incorporated
    $VRTX
    2/13/2026$540.00Perform → Outperform
    Oppenheimer
    Vertex Pharmaceuticals Incorporated
    $VRTX
    1/28/2026$606.00Overweight
    Barclays
    Vertex Pharmaceuticals Incorporated
    $VRTX
    1/22/2026$546.00Sector Perform → Outperform
    RBC Capital Mkts
    Vertex Pharmaceuticals Incorporated
    $VRTX
    1/12/2026Mkt Perform → Outperform
    Bernstein
    Vertex Pharmaceuticals Incorporated
    $VRTX
    1/7/2026$535.00Buy
    UBS
    Vertex Pharmaceuticals Incorporated
    $VRTX
    1/6/2026$548.00Peer Perform → Outperform
    Wolfe Research
    Vertex Pharmaceuticals Incorporated
    $VRTX
    12/3/2025$516.00Equal-Weight → Overweight
    Morgan Stanley
    Vertex Pharmaceuticals Incorporated
    $VRTX
    11/13/2025$495.00Sector Outperform
    Scotiabank
    More analyst ratings

    $VEC
    $VRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and Chief Legal Officer Liu Joy sold $442,396 worth of shares (892 units at $495.96), decreasing direct ownership by 4% to 22,811 units (SEC Form 4)

    4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

    3/4/26 4:21:16 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Liu Joy claimed ownership of 23,703 shares (SEC Form 3)

    3 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

    3/3/26 4:41:53 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CEO & President Kewalramani Reshma sold $19,738,855 worth of shares (40,000 units at $493.47), decreasing direct ownership by 29% to 98,278 units (SEC Form 4)

    4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

    3/3/26 4:34:23 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VEC
    $VRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO & President Kewalramani Reshma bought $3,895,768 worth of shares (10,000 units at $389.58), increasing direct ownership by 9% to 115,968 units (SEC Form 4)

    4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

    8/7/25 4:23:31 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sachs Bruce I bought $1,948,416 worth of shares (5,000 units at $389.68), increasing direct ownership by 12% to 45,000 units (SEC Form 4)

    4 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Issuer)

    8/7/25 4:19:03 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VEC
    $VRTX
    SEC Filings

    View All

    SEC Form 144 filed by Vertex Pharmaceuticals Incorporated

    144 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

    2/27/26 9:50:34 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Vertex Pharmaceuticals Incorporated

    144 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

    2/18/26 12:28:45 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Vertex Pharmaceuticals Incorporated

    144 - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

    2/18/26 10:46:41 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VEC
    $VRTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vertex to Participate in Upcoming March Investor Conferences

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and Financial Officer, and Duncan McKechnie, Chief Commercial Officer, will participate in a fireside chat at the Leerink Global Healthcare Conference on Tuesday, March 10, 2026, at 10:00 a.m. ET. Susie Lisa, Senior Vice President, Investor Relations, and Miroslava Minkova, Executive Director, Investor Relations, will participate in a fireside chat at the Barclays 28th Annual Global Healthcare Conference on Wednesday, March 11, 2026, at 11:30 a.m. ET. About Vertex Vertex is a global biotechnology company that invests in s

    3/5/26 4:00:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

    -Over 90% of patients in the study were opioid free through the end of multimodal treatment with JOURNAVX- -These data have been accepted for oral presentation at the American Academy of Pain Medicine Meeting- Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced data from a Phase 4 study of JOURNAVX® (suzetrigine), a prescription non-opioid pain signal inhibitor for the treatment of moderate-to-severe acute pain, in adults, that demonstrated effective pain management and enabled opioid-free recovery after a broad range of plastic surgical procedures. These data showed that the majority of patients (90.9%) in the study were opioid free through the end of treatment (up to 14

    3/5/26 10:00:00 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced management participation in TD Cowen's 46th Annual Health Care Conference. Reshma Kewalramani, President and Chief Executive Officer will participate in a fireside chat on Tuesday, March 3, 2026, at 9:10 a.m. ET. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com, in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases and conditions.

    2/17/26 4:00:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VEC
    $VRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Vertex Pharma upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Vertex Pharma from Perform to Outperform and set a new price target of $540.00

    2/13/26 7:53:31 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays resumed coverage on Vertex Pharma with a new price target

    Barclays resumed coverage of Vertex Pharma with a rating of Overweight and set a new price target of $606.00

    1/28/26 7:20:21 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vertex Pharma upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Vertex Pharma from Sector Perform to Outperform and set a new price target of $546.00

    1/22/26 8:24:11 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VEC
    $VRTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    January 30, 2025 - FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

    For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain.  Journavx is the first dr

    1/30/25 5:46:14 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    FDA Approval for TRIKAFTA (COPACKAGED) issued to VERTEX PHARMS INC

    Submission status for VERTEX PHARMS INC's drug TRIKAFTA (COPACKAGED) (SUPPL-11) with active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 212273, Application Classification: Labeling

    8/4/23 4:36:00 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VEC
    $VRTX
    Leadership Updates

    Live Leadership Updates

    View All

    Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs

    Experienced industry leader brings extensive expertise in leading breakthrough therapies through clinical development to marketing approval Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the appointment of Antoinette Paone as Chief Development Officer ("CDO") and Head of Regulatory Affairs. Ms. Paone brings extensive experience leading regulatory strategy from clinical development through approval, including her work on Kalydeco and Orkambi at Vertex Pharmaceuticals (NASDAQ:VRTX). She joins Satellos from Generation Bio (NASDAQ:G

    1/29/26 7:00:00 AM ET
    $GBIO
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vertex Appoints Nancy Thornberry to its Board of Directors

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Nancy Thornberry has been appointed to its Board of Directors as an independent director. Ms. Thornberry has more than 35 years of experience in the pharmaceutical and biotech industries, spanning drug discovery, development and commercialization. She founded and served as Chief Executive Officer of Kallyope until 2021 and remains on its Board of Directors and is Chair of Research & Development. Prior to joining Kallyope, Ms. Thornberry spent more than 30 years at Merck & Co., Inc., most recently as Senior Vice President and Global Franchise Head, Diabetes and Endocrinology, with responsibility for discovery and clinical

    12/5/23 4:01:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vertex Appoints Michel Lagarde to its Board of Directors

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today announced that Michel Lagarde has been appointed to its Board of Directors as an independent director. Mr. Lagarde is a senior health care and business leader with global expertise, currently serving as Chief Operating Officer and Executive Vice President of Thermo Fisher Scientific Inc. Prior to Thermo Fisher, Mr. Lagarde served as President and Chief Operating Officer of Patheon, a contract manufacturer to the biopharma industry, and as a Managing Director at JLL Partners, a private equity firm investing in health care services. "We are delighted to have Michel join the Vertex Board. His deep experience across numerous segments of

    10/5/23 8:00:00 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VEC
    $VRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

    SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

    4/10/24 12:14:10 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

    SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

    2/13/24 5:17:31 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Vertex Pharmaceuticals Incorporated (Amendment)

    SC 13G/A - VERTEX PHARMACEUTICALS INC / MA (0000875320) (Subject)

    2/9/24 6:19:03 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VEC
    $VRTX
    Financials

    Live finance-specific insights

    View All

    Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

    — Full year total revenue of $12.0 billion, a 9% increase compared to full year 2024; fourth quarter total revenue of $3.19 billion, a 10% increase compared to fourth quarter 2024 — — Company provides full year 2026 total revenue guidance of $12.95 billion to $13.1 billion, with non-CF products expected to contribute $500 million or more in revenue — — Broad mid- and late-stage clinical pipeline accelerates with multiple proof-of-concept and pivotal programs advancing; on track to complete BLA filing for U.S. accelerated approval of povetacicept in IgAN in the first half of 2026 — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reported consolidated financial results for the f

    2/12/26 4:01:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th

    Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report its fourth quarter and full year 2025 financial results on Thursday, February 12, 2026, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (833) 630-2124 (U.S.) or +1 (412) 317-0651 (International) and reference the "Vertex Pharmaceuticals Fourth Quarter 2025 Earnings Call." The conference call will be webcast live and a link to the webcast can be accessed through Vertex's website at www.vrtx.com in the "Investors" section. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled web

    1/20/26 4:00:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vertex Reports Third Quarter 2025 Financial Results

    — Total revenue of $3.08 billion, an 11% increase compared to Q3 2024 — — Refined full year financial guidance: total revenue guidance now $11.9 to $12.0 billion and total combined non-GAAP R&D, AIPR&D, and SG&A expense guidance now $5.0 to $5.1 billion — — R&D pipeline continues to make progress: five programs in pivotal development and povetacicept Phase 3 IgAN trial full enrollment complete; on track to submit first module of povetacicept IgAN BLA to FDA by end of 2025 — Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) today reported consolidated financial results for the third quarter ended September 30, 2025, and refined full year 2025 financial guidance. "Vertex delivered str

    11/3/25 4:02:00 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care